Overview

Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects

Status:
Completed
Trial end date:
2014-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the comparative single-dose pharmacokinetics (bioequivalence) of lidocaine patch 1.8% (investigational product) versus Lidoderm® (lidocaine patch 5%,reference product).
Phase:
Phase 1
Details
Lead Sponsor:
Scilex Pharmaceuticals, Inc.
Treatments:
Lidocaine